A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.

by Sandra Gordon

New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.

by Laura Gesualdi-Gilmore

Findings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.

by Kyle Bagenstose

Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.

by Thomas Celona

The Cancer Today editors share the most impactful reporting on cancer research from 2024.

by Cancer Today staff

From the Editor-in-Chief

A recently approved therapy targets abnormal enzymes produced by gene defects.

by William G. Nelson, MD, PhD

Forward Look

More patients are receiving CAR T-cell therapy for large B-cell lymphoma.

by Leah Lawrence

Forward Look

Researchers and patients push to move away from maximum tolerated dose in research.

by Natalie Slivinski

Shorter courses of more intense radiation therapy mean fewer visits and less cost for patients. Studies show abbreviated treatments are just as effective as longer courses.

by Stephen Ornes

With targeted therapy options available for a growing number of cancer types, biomarker testing is making a difference for more people with solid cancers.

by Kendall K. Morgan